This Article  • Full text  • PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (979)  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in JAMA  Topic Collections  • Revascularization  • Cardiovascular System  • Surgery  • Surgical Interventions  • Cardiovascular/ Cardiothoracic Surgery  • Randomized Controlled Trial  • Cardiovascular Intervention  • Alert me on articles by topic  Social Bookmarking   What's this?

A Randomized Controlled Trial

Steven R. Steinhubl, MD; Peter B. Berger, MD; J. Tift Mann III, MD; Edward T. A. Fry, MD; Augustin DeLago, MD; Charles Wilmer, MD; Eric J. Topol, MD; for the CREDO Investigators

JAMA. 2002;288:2411-2420.

Context  Following percutaneous coronary intervention (PCI), short-term clopidogrel therapy in addition to aspirin leads to greater protection from thrombotic complications than aspirin alone. However, the optimal duration of combination oral antiplatelet therapy is unknown. Also, although current clinical data suggest a benefit for beginning therapy with a clopidogrel loading dose prior to PCI, the practical application of this therapy has not been prospectively studied.

Objectives  To evaluate the benefit of long-term (12-month) treatment with clopidogrel after PCI and to determine the benefit of initiating clopidogrel with a preprocedure loading dose, both in addition to aspirin therapy.

Design, Setting, and Participants  The Clopidogrel for the Reduction of Events During Observation (CREDO) trial, a randomized, double-blind, placebo-controlled trial conducted among 2116 patients who were to undergo elective PCI or were deemed at high likelihood of undergoing PCI, enrolled at 99 centers in North America from June 1999 through April 2001.

Interventions  Patients were randomly assigned to receive a 300-mg clopidogrel loading dose (n = 1053) or placebo (n = 1063) 3 to 24 hours before PCI. Thereafter, all patients received clopidogrel, 75 mg/d, through day 28. From day 29 through 12 months, patients in the loading-dose group received clopidogrel, 75 mg/d, and those in the control group received placebo. Both groups received aspirin throughout the study.

Main Outcome Measures  One-year incidence of the composite of death, myocardial infarction (MI), or stroke in the intent-to-treat population; 28-day incidence of the composite of death, MI, or urgent target vessel revascularization in the per-protocol population.

Results  At 1 year, long-term clopidogrel therapy was associated with a 26.9% relative reduction in the combined risk of death, MI, or stroke (95% confidence interval [CI], 3.9%-44.4%; P = .02; absolute reduction, 3%). Clopidogrel pretreatment did not significantly reduce the combined risk of death, MI, or urgent target vessel revascularization at 28 days (reduction, 18.5%; 95% CI, -14.2% to 41.8%; P = .23). However, in a prespecified subgroup analysis, patients who received clopidogrel at least 6 hours before PCI experienced a relative risk reduction of 38.6% (95% CI, -1.6% to 62.9%; P = .051) for this end point compared with no reduction with treatment less than 6 hours before PCI. Risk of major bleeding at 1 year increased, but not significantly (8.8% with clopidogrel vs 6.7% with placebo; P = .07).

Conclusions  Following PCI, long-term (1-year) clopidogrel therapy significantly reduced the risk of adverse ischemic events. A loading dose of clopidogrel given at least 3 hours before the procedure did not reduce events at 28 days, but subgroup analyses suggest that longer intervals between the loading dose and PCI may reduce events.

Author Affiliations: Division of Cardiology, School of Medicine, University of North Carolina at Chapel Hill (Dr Steinhubl); Cardiovascular Diseases Division, Mayo Clinic, Rochester, Minn (Dr Berger); WakeMed, Raleigh, NC (Dr Mann); Department of Cardiology, St Vincent Hospital, Indianapolis, Ind (Dr Fry); Cardiology Division, Albany Medical Center, Albany, NY (Dr DeLago); Atlanta Medical Center, Atlanta, Ga (Dr Wilmer); and Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio (Dr Topol).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Clopidogrel and Percutaneous Coronary Interventions
Robin P. Choudhury
JAMA. 2003;289(15):1925.
EXTRACT | FULL TEXT  

Clopidogrel and Percutaneous Coronary Interventions
John F. P. Bridges
JAMA. 2003;289(15):1925-1926.
EXTRACT | FULL TEXT  

Clopidogrel and Percutaneous Coronary Interventions
Javier Borja, Iñaki Pérez, and Guillermo De la Cruz
JAMA. 2003;289(15):1926.
EXTRACT | FULL TEXT  

Clopidogrel and Percutaneous Coronary Interventions
Brian Y. L. Wong and Eric A. Cohen
JAMA. 2003;289(15):1926.
EXTRACT | FULL TEXT  

Clopidogrel and Percutaneous Coronary Interventions
Attila Dirkali and Victor A. Umans
JAMA. 2003;289(15):1926.
EXTRACT | FULL TEXT  

Glycoprotein IIb/IIIa Inhibition in Percutaneous Coronary Interventions—Reply
A. Michael Lincoff and Eric J. Topol
JAMA. 2003;290(11):1451-1452.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Kushner et al.
J Am Coll Cardiol 2009;54:2205-2241.
FULL TEXT  

Optimizing Antiplatelet Therapy in High-Risk Patients With Atrial Fibrillation: Insights From Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)
Seet and Chen
Stroke 2009;40:3883-3885.
FULL TEXT  

Current practice and limitations of dual antiplatelet therapy in acute coronary syndrome
Hamm
Eur Heart J Suppl 2009;11:G4-G8.
ABSTRACT | FULL TEXT  

Randomized Comparison of Percutaneous Coronary Intervention With Coronary Artery Bypass Grafting in Diabetic Patients: 1-Year Results of the CARDia (Coronary Artery Revascularization in Diabetes) Trial
Kapur et al.
J Am Coll Cardiol 2009;0:j.jacc.2009.10.014v1-15241.
ABSTRACT | FULL TEXT  

The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis.
Berger et al.
J Am Coll Cardiol 2009;54:1935-1945.
ABSTRACT | FULL TEXT  

Intravenous Platelet Blockade with Cangrelor during PCI
Bhatt et al.
NEJM 2009;0:NEJMoa0908629v1-1.
ABSTRACT | FULL TEXT  

Dual antiplatelet therapy in coronary artery disease: A case-based approach
RAYMOND and MENON
Cleveland Clinic Journal of Medicine 2009;76:663-670.
ABSTRACT | FULL TEXT  

Postoperative blood loss in patients undergoing coronary artery bypass surgery after preoperative treatment with clopidogrel. A prospective randomised controlled study
Firanescu et al.
Eur. J. Cardiothorac. Surg. 2009;36:856-862.
ABSTRACT | FULL TEXT  

Reoperation for Bleeding in Patients Undergoing Coronary Artery Bypass Surgery: Incidence, Risk Factors, Time Trends, and Outcomes
Mehta et al.
Circ Cardiovasc Qual Outcomes 2009;2:583-590.
ABSTRACT | FULL TEXT  

Hunting for the "Sweet Spot" in P2Y12 Receptor Blockade
Simon and Parikh
J Am Coll Cardiol 2009;54:1447-1449.
FULL TEXT  

Antiplatelet agents used for early intervention in acute coronary syndrome: Myocardial salvage versus bleeding complications.
Aranki and Body
J. Thorac. Cardiovasc. Surg. 2009;138:807-810.e7.
FULL TEXT  

Acute Coronary Syndromes: Diagnosis and Management, Part I
Kumar and Cannon
Mayo Clin Proc. 2009;84:917-938.
ABSTRACT | FULL TEXT  

Dual antiplatelet therapy for more than 12 months after percutaneous coronary intervention: insights from the Guthrie PCI Registry
Harjai et al.
Heart 2009;95:1579-1586.
ABSTRACT | FULL TEXT  

Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial
Moukarbel et al.
Eur Heart J 2009;30:2226-2232.
ABSTRACT | FULL TEXT  

Review: Platelet Function Testing and Implications for Clinical Practice
Collet and Montalescot
J CARDIOVASC PHARMACOL THER 2009;14:157-169.
ABSTRACT  

P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use
Wallentin
Eur Heart J 2009;30:1964-1977.
ABSTRACT | FULL TEXT  

Personalized medicine and antiplatelet therapy: ready for prime time?
Verstuyft et al.
Eur Heart J 2009;30:1943-1963.
FULL TEXT  

Prediction of Prasugrel Active Metabolite Concentrations From 2 Downstream Inactive Metabolite Concentrations Using Multilinear Regression Analysis
Ernest et al.
J Clin Pharmacol 2009;49:973-983.
ABSTRACT | FULL TEXT  

Population Pharmacokinetic Analyses to Evaluate the Influence of Intrinsic and Extrinsic Factors on Exposure of Prasugrel Active Metabolite in TRITON-TIMI 38
Wrishko et al.
J Clin Pharmacol 2009;49:984-998.
ABSTRACT | FULL TEXT  

Combining Antiplatelet and Anticoagulant Therapies.
Holmes et al.
J Am Coll Cardiol 2009;54:95-109.
ABSTRACT | FULL TEXT  

Percutaneous coronary intervention versus coronary-artery bypass grafting.
Bhindi et al.
NEJM 2009;360:2672-2673.
FULL TEXT  

Update on dual antiplatelet therapy for percutaneous coronary intervention
Prasad and Holmes
Heart 2009;95:861-865.
FULL TEXT  

Bedside Evaluation of Thienopyridine Antiplatelet Therapy
Price
Circulation 2009;119:2625-2632.
FULL TEXT  

Clinical Effectiveness of Coronary Stents in Elderly Persons: Results From 262,700 Medicare Patients in the American College of Cardiology-National Cardiovascular Data Registry
Douglas et al.
J Am Coll Cardiol 2009;53:1629-1641.
ABSTRACT | FULL TEXT  

The dangers of stopping clopidogrel perioperatively: a cardiologist's perspective
Cleanthis and Flather
Clin Risk 2009;15:106-108.
FULL TEXT  

Clopidogrel Inhibits CYP2C19-Dependent Hydroxylation of Omeprazole Related to CYP2C19 Genetic Polymorphisms
Chen et al.
J Clin Pharmacol 2009;49:574-581.
ABSTRACT | FULL TEXT  

Aspirin Plus Clopidogrel and Risk of Infection After Coronary Artery Bypass Surgery
Blasco-Colmenares et al.
Arch Intern Med 2009;169:788-795.
ABSTRACT | FULL TEXT  

Clopidogrel in acute coronary syndromes
Chua and Ignaszewski
BMJ 2009;338:b1180-b1180.
FULL TEXT  

Avoiding and Managing Bleeding Complications in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes
Potsis et al.
ANGIOLOGY 2009;60:148-158.
ABSTRACT  

Prasugrel: A New Thienopyridine Inhibitor
Veverka and Hammer
Journal of Pharmacy Practice 2009;22:158-165.
ABSTRACT  

Gastrointestinal Complications After 3 Months of Dual Antiplatelet Therapy for Drug-eluting Stents as Assessed by Wireless Capsule Endoscopy
Seddighzadeh et al.
CLIN APPL THROMB HEMOST 2009;15:171-176.
ABSTRACT  

Randomized Comparison of Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With High Post-Treatment Platelet Reactivity Results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) Randomized Study.
Jeong et al.
J Am Coll Cardiol 2009;53:1101-1109.
ABSTRACT | FULL TEXT  

Advanced Age, Antithrombotic Strategy, and Bleeding in Non-ST-Segment Elevation Acute Coronary Syndromes: Results From the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Trial
Lopes et al.
J Am Coll Cardiol 2009;53:1021-1030.
ABSTRACT | FULL TEXT  

Risk of Adverse Outcomes Associated With Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Acute Coronary Syndrome
Ho et al.
JAMA 2009;301:937-944.
ABSTRACT | FULL TEXT  

The Role of Aspirin in Cardiovascular Disease Prevention in Women
Hopkins and Limacher
AMERICAN JOURNAL OF LIFESTYLE MEDICINE 2009;3:123-134.
ABSTRACT  

Thrombosis and Antithrombotic Therapy in Women
Bailey et al.
Arterioscler. Thromb. Vasc. Bio. 2009;29:284-288.
ABSTRACT | FULL TEXT  

Antiplatelet Therapy and Stent Thrombosis After Sirolimus-Eluting Stent Implantation
Kimura et al.
Circulation 2009;119:987-995.
ABSTRACT | FULL TEXT  

Impact of preoperative clopidogrel in off pump coronary artery bypass surgery: a propensity score analysis.
Vaccarino et al.
J. Thorac. Cardiovasc. Surg. 2009;137:309-313.
ABSTRACT | FULL TEXT  

Expanding the Recognition and Assessment of Bleeding Events Associated With Antiplatelet Therapy in Primary Care
Cohen
Mayo Clin Proc. 2009;84:149-160.
ABSTRACT | FULL TEXT  

Genetic Determinants of Response to Clopidogrel and Cardiovascular Events
Simon et al.
NEJM 2009;360:363-375.
ABSTRACT | FULL TEXT  

Patients with peripheral arterial disease in the CHARISMA trial
Cacoub et al.
Eur Heart J 2009;0:ehn534v1-10.
ABSTRACT | FULL TEXT  

Platelet P2Y12 Receptor Influences the Vessel Wall Response to Arterial Injury and Thrombosis
Evans et al.
Circulation 2009;119:116-122.
ABSTRACT | FULL TEXT  

An Appraisal of Dual Antiplatelet Therapy with Clopidogrel and Aspirin for Prevention of Cardiovascular Events
Terpening
J Am Board Fam Med 2009;22:51-56.
ABSTRACT | FULL TEXT  

Antiplatelet Agents in the Perioperative Period
O'Riordan et al.
Arch Surg 2009;144:69-76.
ABSTRACT | FULL TEXT  

P2Y12 Inhibitors in Cardiovascular Disease: Focus on Prasugrel
Scott et al.
The Annals of Pharmacotherapy 2009;43:64-76.
ABSTRACT | FULL TEXT  

Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual Antiplatelet Therapy After Drug-Eluting Stents Should Be Continued for More Than One Year and Preferably Indefinitely
Chhatriwalla and Bhatt
Circ Cardiovasc Interv 2008;1:217-225.
FULL TEXT  

The Antiplatelet Effect of Higher Loading and Maintenance Dose Regimens of Clopidogrel: The PRINC (Plavix Response in Coronary Intervention) Trial
Gladding et al.
J Am Coll Cardiol Intv 2008;1:612-619.
ABSTRACT | FULL TEXT  

Patent Foramen Ovale and Cryptogenic Stroke: To Close or Not to Close? Closure: What Else!
Windecker and Meier
Circulation 2008;118:1989-1997.
FULL TEXT  

Cost-Effectiveness of Clopidogrel: Seeing through the Smoke
Goldman and Gaspoz
Med Decis Making 2008;28:803-809.
ABSTRACT  

Long-term treatment strategies for atherothrombotic disease: do platelets define the course?
Zimarino and De Caterina
Eur Heart J Suppl 2008;10:I8-I13.
ABSTRACT | FULL TEXT  

Benefits and risks with antiplatelet therapy: how great a problem is bleeding?
Husted
Eur Heart J Suppl 2008;10:I19-I24.
ABSTRACT | FULL TEXT  

European perspective on the use of antiplatelet agents in atherothrombotic disease
Sanz-Ruiz and Fernandez-Aviles
Eur Heart J Suppl 2008;10:I14-I18.
ABSTRACT | FULL TEXT  

Duration of antiplatelet therapy following intracoronary stenting: are changes needed?
Byrne and Kastrati
Eur Heart J Suppl 2008;10:I25-I29.
ABSTRACT | FULL TEXT  

Impact of Pretreatment With Clopidogrel on Initial Patency and Outcome in Patients Treated With Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction: A Systematic Review
Vlaar et al.
Circulation 2008;118:1828-1836.
ABSTRACT | FULL TEXT  

Optimizing Clopidogrel Therapy Before Stent Implantation: Should Clinical Setting Be Taken Into Account?
Aradi et al.
J Am Coll Cardiol 2008;52:1349-1349.
FULL TEXT  

Reply
Bonello et al.
J Am Coll Cardiol 2008;52:1349-1350.
FULL TEXT  

Short- and long-term efficacy of aspirin and clopidogrel for thromboprophylaxis for mechanical heart valves: an in vivo study in swine.
McKellar et al.
J. Thorac. Cardiovasc. Surg. 2008;136:908-914.
ABSTRACT | FULL TEXT  

Review: Recurrent stroke: where do we stand with the secondary prevention of noncardioembolic ischaemic strokes?
Talelli and Greenwood
Ther Adv Cardiovasc Dis 2008;2:387-405.
ABSTRACT  

A Novel Endovascular Device for Emboli Rerouting: Part I: Evaluation in a Swine Model
Grad et al.
Stroke 2008;39:2860-2866.
ABSTRACT | FULL TEXT  

Long-Term Impact of Drug-Eluting Stents Versus Bare-Metal Stents on All-Cause Mortality
Shishehbor et al.
J Am Coll Cardiol 2008;52:1041-1048.
ABSTRACT | FULL TEXT  

A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study
Angiolillo et al.
Eur Heart J 2008;29:2202-2211.
ABSTRACT | FULL TEXT  

Increased Major Bleeding Complications Related to Triple Antithrombotic Therapy Usage in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Artery Stenting
Manzano-Fernandez et al.
Chest 2008;134:559-567.
ABSTRACT | FULL TEXT  

Survival Benefit With Concomitant Clopidogrel and Glycoprotein IIb/IIIa Inhibitor Therapy at Ad Hoc Percutaneous Coronary Intervention
Gumina et al.
Mayo Clin Proc. 2008;83:995-1001.
ABSTRACT | FULL TEXT  

Incidence and Clinical Impact of Dual Nonresponsiveness to Aspirin and Clopidogrel in Patients With Drug-Eluting Stents
Gori et al.
J Am Coll Cardiol 2008;52:734-739.
ABSTRACT | FULL TEXT  

Role of Reticulated Platelets and Platelet Size Heterogeneity on Platelet Activity After Dual Antiplatelet Therapy With Aspirin and Clopidogrel in Patients With Stable Coronary Artery Disease
Guthikonda et al.
J Am Coll Cardiol 2008;52:743-749.
ABSTRACT | FULL TEXT  

Bivalirudin versus Unfractionated Heparin during Percutaneous Coronary Intervention
Kastrati et al.
NEJM 2008;359:688-696.
ABSTRACT | FULL TEXT  

Dual Antiplatelet Therapy Monitoring for Neurointerventional Procedures Using a Point-of-Care Platelet Function Test: A Single-Center Experience
Lee et al.
Am. J. Neuroradiol. 2008;29:1389-1394.
ABSTRACT | FULL TEXT  

Progress Is Precarious
Head and Barash
Anesth. Analg. 2008;107:362-364.
FULL TEXT  

Coronary Artery Stents: Part I. Evolution of Percutaneous Coronary Intervention
Newsome et al.
Anesth. Analg. 2008;107:552-569.
ABSTRACT | FULL TEXT  

Coronary Artery Stents: II. Perioperative Considerations and Management
Newsome et al.
Anesth. Analg. 2008;107:570-590.
ABSTRACT | FULL TEXT  

Optimizing antithrombotic therapy in patients with non-ST-segment elevation acute coronary syndrome
Dobesh et al.
Am J Health Syst Pharm 2008;65:S22-S28.
ABSTRACT | FULL TEXT  

Determinants of thrombin generation, fibrinolytic activity, and endothelial dysfunction in patients on dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad
Yano et al.
Eur Heart J 2008;29:1729-1738.
ABSTRACT | FULL TEXT  

Guideline on antiplatelet and anticoagulation management in cardiac surgery.
Dunning et al.
Eur. J. Cardiothorac. Surg. 2008;34:73-92.
ABSTRACT | FULL TEXT  

Aspirin in coronary artery bypass surgery: new aspects of and alternatives for an old antithrombotic agent.
Zimmermann et al.
Eur. J. Cardiothorac. Surg. 2008;34:93-108.
ABSTRACT | FULL TEXT  

2007 Guideline Update for Unstable Angina/Non-ST-Segment Elevation Myocardial Infarction: Focus on Antiplatelet and Anticoagulant Therapies
Coons and Battistone
The Annals of Pharmacotherapy 2008;42:989-1001.
ABSTRACT | FULL TEXT  

Benefits and limitations of current antiplatelet therapies
Nappi
Am J Health Syst Pharm 2008;65:S5-S10.
ABSTRACT | FULL TEXT  

Dual antiplatelet therapy with clopidogrel and aspirin
Sullivan and Amarshi
Am J Health Syst Pharm 2008;65:1134-1143.
ABSTRACT | FULL TEXT  

Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions.
Brar et al.
J Am Coll Cardiol 2008;51:2220-2227.
ABSTRACT | FULL TEXT  

Clopidogrel pre-treatment in stable angina: for all patients >6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8
Widimsky et al.
Eur Heart J 2008;29:1495-1503.
ABSTRACT | FULL TEXT  

Impact of bivalirudin or unfractionated heparin on platelet aggregation in patients pretreated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention
Sibbing et al.
Eur Heart J 2008;29:1504-1509.
ABSTRACT | FULL TEXT  

Routine pre-treatment with clopidogrel before diagnostic coronary angiography: the question is right, but what about the answer?
Schiele et al.
Eur Heart J 2008;29:1475-1477.
FULL TEXT  

Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents
Natarajan et al.
Diabetes and Vascular Disease Research 2008;5:138-144.
ABSTRACT  

Pharmacoeconomic Concepts in Antiplatelet Therapy: Understanding Cost-Effectiveness Analyses Using Clopidogrel as an Example
Weintraub
J CARDIOVASC PHARMACOL THER 2008;13:107-119.
ABSTRACT  

Aspirin, Clopidogrel, and Warfarin: Is the Combination Appropriate and Effective or Inappropriate and Too Dangerous?
Hermosillo and Spinler
The Annals of Pharmacotherapy 2008;42:790-805.
ABSTRACT | FULL TEXT  

Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Patrono et al.
Chest 2008;133:199S-233S.
ABSTRACT | FULL TEXT